QP34563457 / Viva Biotech - LARVOL DELTA

Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer (MedPageToday) - "According to JCO associate editor Andrew H. Ko, MD, 'Continuation of trastuzumab in the second-line setting, in combination with paclitaxel/ramucirumab, represents a promising strategy for patients with advanced HER2-positive gastroesophageal cancer. Further prospective randomized data are required to validate this approach.''"

Media quote

Treatment Strategies in HER2+ Colorectal Cancer: An Expert Case-Based Discussion : Episode 11: SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer (Cancer Network) - "Cathy Eng, MD...we talked about the PARADIGM trial (NCT02394795), and we've been talking a lot about tucatinib and T-DXd [trastuzumab deruxtecan], what about patients who are seeking a third-line option who are not HER2+ [human epidermal growth factor receptor 2-positive]? Can you tell us a little bit about the SUNLIGHT trial (NCT04737187), which was recently presented, and what this means in regard to the current sequence of therapy and paradigm of care?"

Video

Treatment Strategies in HER2+ Colorectal Cancer: An Expert Case-Based Discussion : Episode 4: MOUNTAINEER: Tucatinib Plus Trastuzumab in HER2+ Metastatic Colorectal Cancer (Cancer Network) - "Cathy Eng, MD, FACP, FASCO: Dr Foote, can you review recent efficacy and safety data from the MOUNTAINEER study, the trial that we’ve been mentioning, regarding tucatinib [Tukysa] and HER2 [human epidermal growth factor receptor 2]–positive metastatic colorectal carcinoma?...Suneel Kamath, MD: Dr Foote stole my thunder a little bit. Diarrhea is by far the biggest and most common toxicity."

Video

New Agents “Beat the Socks Off” Standard Chemo in TNBC - "Recent advances, such as the development of antibody-drug conjugates, are changing the landscape in triple-negative breast cancer (TNBC). Erika Hamilton, MD...shares her thoughts on how treatment is evolving to 'beat the socks' off of previous standards of care. Dr. Hamilton discusses how sacituzumab govitecan and trastuzumab deruxtecan are moving into early, first-line treatment for both curative and metastatic TNBC, as well as other antibody-drug conjugates that are in the pipeline."

Video

Using MRD Negativity to Discontinue Maintenance Treatment in Multiple Myeloma (Targeted Oncology) - "In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma....Derman: We call this a prospective trial using multimodal MRD negativity to guide discontinuation of maintenance therapy in myeloma.... When I say multimodal, what I mean is using the different tools at our disposal that are available in the clinic right now as part of a standard of care approach to guide discontinuation."

Interview

’New Standard of Care’ for HER2-Mutant NSCLC? (Medscape) - "'These results establish the new standard of care for patients with NSCLC harboring HER2 mutations,' Antonio Passaro, MD, PhD...write in an accompanying editorial. The findings 'appear robust and potentially could extend to patients who have not previously received systemic treatment.'"

Media quote

[VIRTUAL] Preclinical evaluation of trastuzumab/pertuzumab/IL-15, a new trifunctional fusion protein, for HER2 positive cancer therapy (AACR 2021) - "Our data demonstrated that the trifunctional fusion protein QP34563457 have higher biological activity than single anti-HER2 antibody T-mab or P-mab and their combination, suggesting a more effective HER2 (+) cancer treatment potential. In combination with a dosing matching IL-15 activity, QP34563457 is expected to engage immune cells in a HER2 (+) tumor targeted manner and exhibit synergistic effects by bispecific targeting on HER2 (+) tumors as well. The yield and physiochemical properties of QP34563457 is up to the industrial production standard."

Preclinical • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2 • IL15 • IL2